Pyxis Oncology (PYXS) Non-Current Assets (2020 - 2026)

Pyxis Oncology (PYXS) has reported Non-Current Assets for 7 consecutive years, with $18.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 21.8% year-over-year to $18.2 million in Q2 2026; TTM through Jun 2026 was $83.4 million, a 29.59% decrease from a year earlier, with the FY2025 full-year figure at $19.4 million, down 21.53% from the prior year.
• Non-Current Assets was $18.2 million for Q2 2026 at Pyxis Oncology, down from $19.4 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $49.1 million in Q4 2023 and troughed at $1.4 million in Q1 2022.
• A 5-year average of $28.6 million and a median of $24.7 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 1743.56% in 2023 and sank 51.49% in 2025, its largest moves.
• Over 5 years, Non-Current Assets stood at $24.8 million in 2022, then jumped by 98.34% to $49.1 million in 2023, then sank by 49.63% to $24.7 million in 2024, then retreated by 21.53% to $19.4 million in 2025, then decreased by 6.32% to $18.2 million in 2026.
• The last three Non-Current Assets figures came in at $18.2 million (Q2 2026), $19.4 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.